These methylation changes have been deeply investigated, with a particular focus on specific regions, such as the promoter region of the CDKN2A gene (Cyclin-Dependent Kinase Inhibitor 2A), which has been identified as one of the first potential new biomarkers for the early detection of LC [52,54]. Here, CDKN2A is linked to laryngotracheoesophageal cleft.